Answers are grounded in this paper and cite their sources.
Immunotherapies for urothelial carcinoma have shown clinical efficacy in select patients as well as a manageable safety profile. Studies are ongoing with the aim of expanding the proof of efficacy in metastatic disease and providing additional treatment options for patients with earlier stages of urothelial carcinoma.
No takes yet. Share an insight, caveat, or question.
Siefker‐Radtke et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: